3-Bromopyruvic acid
CAS No. 1113-59-3
3-Bromopyruvic acid( Bromopyruvic acid | Hexokinase II Inhibitor II 3-BP )
Catalog No. M20515 CAS No. 1113-59-3
3-Bromopyruvic acid is a hexokinase II inhibitor with Ki of 2.4 mM for glycolysis/hexokinase inhibition. It is inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 38 | In Stock |
|
| 1G | 45 | In Stock |
|
Biological Information
-
Product Name3-Bromopyruvic acid
-
NoteResearch use only, not for human use.
-
Brief Description3-Bromopyruvic acid is a hexokinase II inhibitor with Ki of 2.4 mM for glycolysis/hexokinase inhibition. It is inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs.
-
Description3-Bromopyruvic acid is a hexokinase II inhibitor with Ki of 2.4 mM for glycolysis/hexokinase inhibition. It is inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs.
-
In VitroCell Viability Assay Cell Line:MCF-7 and MDA-MB-231 cells Concentration:40, 80, 160 or 320 μM Incubation Time:24 hours Result:3-Bromopyruvate (80 and 160 μmol/l) and TRAIL (400 ng/ml) significantly inhibited cell viability.
-
In VivoAnimal Model:Female nude mice (BALB/c; 4-5-weeks old and 18-20 g)Dosage:8 mg/kg Administration:I.p.; every 4 days for 28 days Result:Showed antitumor efficacy in tumor xenografts.
-
SynonymsBromopyruvic acid | Hexokinase II Inhibitor II 3-BP
-
PathwayOthers
-
TargetOther Targets
-
Recptorhexokinase II
-
Research AreaCancer
-
Indicationantineoplastic
Chemical Information
-
CAS Number1113-59-3
-
Formula Weight166.96
-
Molecular FormulaC3H3BrO3
-
Purity>98% (HPLC)
-
SolubilityH2O:32 mg/mL (191.66 mM)
-
SMILESOC(=O)C(=O)CBr
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Remimazolam
Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?
-
Lucidenic acid O
Lucidenic acid O is a terpene compound, is a DNA polymerases inhibitor. Lucidenic lactone inhibits calf DNA polymerase-α, rat DNA polymerase-β, and HIV-1 reverse transcriptase with IC50 values of 42 μM, 99 μM, and 69 μM, respectively.
-
NCGC00229600
NCGC00229600 is an allosteric inverse thyrotropin receptor (TSHR) agonist.
Cart
sales@molnova.com